Clinical Trial Record

Return to Clinical Trials

Evaluation of Prognosis With Integrated MRI/PET in Patients With Pancreatic Cancer


2014-08


2016-04


2016-08


100

Study Overview

Evaluation of Prognosis With Integrated MRI/PET in Patients With Pancreatic Cancer

The aim of this study was to evaluate MR/PET with both functional and molecular imaging on the prediction of prognosis in patients with suspected pancreatic cancer.

The results of MR/PET will be compared prospectively to dedicated MDCT or MR imaging, pathologic results, and clinical outcomes to assess the value of MR/PET in pancreatic cancers.

  • Pancreatic Cancer
  • DEVICE: The imaging biomarkers determined by MR-PET
  • 201407052MINC

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates Results Reporting Dates Study Record Updates

2015-09-08  

N/A  

2016-04-12  

2015-09-15  

N/A  

2016-04-14  

2015-09-16  

N/A  

2016-04  

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

Design Details

Primary Purpose:
N/A


Allocation:
N/A


Interventional Model:
N/A


Masking:
N/A


Arms and Interventions

Participant Group/ArmIntervention/Treatment
Primary Outcome MeasuresMeasure DescriptionTime Frame
The tumor recurrence rate after operation at 6 months6 months
Secondary Outcome MeasuresMeasure DescriptionTime Frame
The overall survival after operation at 6 months6 months

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Name: Ting-Fang Shih, MD

Phone Number: +886-2-23123456

Email: ttfshih@ntu.edu.tw

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person’s general health condition or prior treatments.

Ages Eligible for Study:
ALL

Sexes Eligible for Study:
20 Years

Accepts Healthy Volunteers:

    Inclusion Criteria:
    1. Diagnosed as pancreatic cancer 2. Between 20~90 years old 3. ECOG 0-2 4. Normal renal function 5. Measurable tumor size (>1cm)
    Exclusion Criteria:
    1. Contraindication for MRI exam 2. Claustrophobia 3. Renal insufficiency 4. Other malignancy 5. Pregnancy and lactating women

Collaborators and Investigators

This is where you will find people and organizations involved with this study.


    • PRINCIPAL_INVESTIGATOR: Ting-Fang Shih, MD, Department of Medical Imaging, National Taiwan University Hospital

    Publications

    The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

    General Publications

    No publications available